This result indicated that the new protocol was very accurate and on par with the comparison method
[DOI] [PMC free article] [PubMed] [Google Scholar] 45.Stephens F.B., Wall B.T., Marimuthu K., Shannon C.E., Constantin-Teodosiu D., Macdonald I.A., Greenhaff P.L
Victozas patent in the US and Europe expired in late 2023, paving the way for companies like Teva to pursue generic versions
The full scope at Ascend includes: Obesity and overweight with comorbidities - full workup, GLP-1 candidacy assessment, lifestyle integration Type 2 diabetes with weight management goals - GLP-1 medications often address both indications simultaneously Hypertension tied to weight - coordinated medication review and lifestyle work Dyslipidemia and metabolic syndrome - lipids often improve markedly with weight loss Prediabetes - HbA1c 5.7-6.4% range, where intervention can prevent progression Fatty liver disease (MASLD) - weight loss is the primary intervention
Retrieved from ScienceDirect ScienceDirect
GLP-1 agonists are promising for MASH treatment because they target multiple aspects of the disease, including fat accumulation, inflammation, and insulin resistance, which are all key factors in MASH progression
